PH12014501164A1 - Anti-cd98 antibodies and methods of use thereof - Google Patents
Anti-cd98 antibodies and methods of use thereofInfo
- Publication number
- PH12014501164A1 PH12014501164A1 PH12014501164A PH12014501164A PH12014501164A1 PH 12014501164 A1 PH12014501164 A1 PH 12014501164A1 PH 12014501164 A PH12014501164 A PH 12014501164A PH 12014501164 A PH12014501164 A PH 12014501164A PH 12014501164 A1 PH12014501164 A1 PH 12014501164A1
- Authority
- PH
- Philippines
- Prior art keywords
- antibodies
- methods
- cancers
- bind
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563443P | 2011-11-23 | 2011-11-23 | |
| PCT/US2012/066347 WO2013078377A1 (en) | 2011-11-23 | 2012-11-21 | Anti-cd98 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12014501164A1 true PH12014501164A1 (en) | 2014-10-20 |
Family
ID=47295209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12014501164A PH12014501164A1 (en) | 2011-11-23 | 2014-05-23 | Anti-cd98 antibodies and methods of use thereof |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2782935A1 (ru) |
| JP (1) | JP2015501639A (ru) |
| KR (1) | KR20140125351A (ru) |
| CN (1) | CN104302669A (ru) |
| AU (1) | AU2012340623A1 (ru) |
| BR (1) | BR112014012590A8 (ru) |
| CA (1) | CA2856873A1 (ru) |
| HK (1) | HK1202877A1 (ru) |
| IL (1) | IL232755A0 (ru) |
| MX (1) | MX2014006272A (ru) |
| PH (1) | PH12014501164A1 (ru) |
| RU (1) | RU2014124530A (ru) |
| SG (1) | SG11201402619VA (ru) |
| WO (1) | WO2013078377A1 (ru) |
| ZA (1) | ZA201403760B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2634098T3 (es) | 2011-01-14 | 2017-09-26 | The Regents Of The University Of California | Anticuerpos terapéuticos contra la proteína ROR-1 y procedimientos para el uso de los mismos. |
| WO2014197871A2 (en) * | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates, compositions and methods of use |
| US10781259B2 (en) | 2013-06-06 | 2020-09-22 | Magenta Therapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
| JP2017114763A (ja) * | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| CN107207591A (zh) * | 2014-12-10 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 血脑屏障受体抗体及使用方法 |
| PT3336185T (pt) * | 2015-08-10 | 2022-01-27 | Univ Osaka | Anticorpo |
| CN105385694B (zh) * | 2015-11-20 | 2019-01-18 | 中国人民解放军第四军医大学 | 抗人cd98单克隆抗体98-3h3轻、重链可变区基因及其应用 |
| EP3468596A2 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| CN109562169A (zh) * | 2016-06-08 | 2019-04-02 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
| RU2764651C2 (ru) | 2016-06-08 | 2022-01-19 | Эббви Инк. | Антитела к в7-н3 и конъюгаты антитела и лекарственного средства |
| CA3027046A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
| SG11202007363TA (en) | 2018-02-07 | 2020-08-28 | Regeneron Pharma | Methods and compositions for therapeutic protein delivery |
| EP3715370A1 (en) * | 2019-03-28 | 2020-09-30 | Technische Universität München | High affinity anticalins directed against human cd98hc |
| IL297143A (en) * | 2020-04-08 | 2022-12-01 | Janssen Biotech Inc | Anti-cd98 antibodies and their uses |
| UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| WO2022252167A1 (en) * | 2021-06-02 | 2022-12-08 | Huahui Health Ltd. | Anti-cd98 antibodies and uses thereof |
| CN115772541A (zh) * | 2021-12-17 | 2023-03-10 | 百奥赛图江苏基因生物技术有限公司 | Cd98hc基因人源化非人动物的构建方法及应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| DE69233254T2 (de) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| CA2122732C (en) | 1991-11-25 | 2008-04-08 | Marc D. Whitlow | Multivalent antigen-binding proteins |
| DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| AU2002330162B2 (en) | 2001-10-01 | 2008-08-07 | Takeda Pharmaceutical Company Limited | Multi-chain eukaryotic display vectors and uses thereof |
| US20040005709A1 (en) | 2001-10-24 | 2004-01-08 | Hoogenboom Henricus Renerus Jacobus Mattheus | Hybridization control of sequence variation |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| CA2580141C (en) | 2004-09-23 | 2013-12-10 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2622755C (en) | 2005-10-07 | 2017-01-31 | Exelixis, Inc. | Azetidines as mek inhibitors |
| TWI390034B (zh) | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
| GB0615662D0 (en) * | 2006-08-07 | 2006-09-13 | Affitech As | Antibody |
| JPWO2011118804A1 (ja) * | 2010-03-26 | 2013-07-04 | 国立大学法人徳島大学 | 新規抗ｃｄ９８抗体とその用途 |
-
2012
- 2012-11-21 AU AU2012340623A patent/AU2012340623A1/en not_active Abandoned
- 2012-11-21 MX MX2014006272A patent/MX2014006272A/es unknown
- 2012-11-21 KR KR1020147016959A patent/KR20140125351A/ko not_active Application Discontinuation
- 2012-11-21 BR BR112014012590A patent/BR112014012590A8/pt not_active IP Right Cessation
- 2012-11-21 SG SG11201402619VA patent/SG11201402619VA/en unknown
- 2012-11-21 EP EP12795978.1A patent/EP2782935A1/en not_active Withdrawn
- 2012-11-21 CA CA2856873A patent/CA2856873A1/en not_active Abandoned
- 2012-11-21 WO PCT/US2012/066347 patent/WO2013078377A1/en active Application Filing
- 2012-11-21 RU RU2014124530/10A patent/RU2014124530A/ru not_active Application Discontinuation
- 2012-11-21 JP JP2014543574A patent/JP2015501639A/ja active Pending
- 2012-11-21 CN CN201280067876.7A patent/CN104302669A/zh active Pending
-
2014
- 2014-05-22 IL IL232755A patent/IL232755A0/en unknown
- 2014-05-22 ZA ZA2014/03760A patent/ZA201403760B/en unknown
- 2014-05-23 PH PH12014501164A patent/PH12014501164A1/en unknown
-
2015
- 2015-03-31 HK HK15103289.7A patent/HK1202877A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014012590A2 (pt) | 2017-06-20 |
| IL232755A0 (en) | 2014-07-31 |
| KR20140125351A (ko) | 2014-10-28 |
| NZ626513A (en) | 2017-02-24 |
| SG11201402619VA (en) | 2014-10-30 |
| RU2014124530A (ru) | 2015-12-27 |
| EP2782935A1 (en) | 2014-10-01 |
| HK1202877A1 (en) | 2015-10-09 |
| AU2012340623A1 (en) | 2014-07-17 |
| MX2014006272A (es) | 2014-10-24 |
| BR112014012590A8 (pt) | 2017-12-19 |
| WO2013078377A9 (en) | 2013-08-08 |
| WO2013078377A1 (en) | 2013-05-30 |
| CN104302669A (zh) | 2015-01-21 |
| JP2015501639A (ja) | 2015-01-19 |
| ZA201403760B (en) | 2017-09-27 |
| CA2856873A1 (en) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
| MX2015017331A (es) | Anticuerpos anti fc similar a receptor 5 (fcrh5). | |
| MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
| MY164647A (en) | Cea antibodies | |
| MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
| MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
| NZ702748A (en) | Cd33 antibodies and use of same to treat cancer | |
| MX357391B (es) | Anticuerpos anti-erbb3 y usos de los mismos. | |
| EP2569434A4 (en) | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | |
| MX2014008102A (es) | Inmunoglobulinas de dominio variable dual contra receptores. | |
| MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
| MX336001B (es) | Anticuerpos anti-axl y metodos de uso. | |
| MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
| PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
| MX2015013166A (es) | Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17. | |
| PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
| MX340555B (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
| MX2016004853A (es) | Metodos de uso de anticuerpos anti-ly6e. | |
| MX2014014376A (es) | Anticuerpos de anti-biotina y metodos de uso. | |
| MX2012011829A (es) | Anticuerpos de anti-poliubiquitina y metodos de uso. | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. |